Levosimendan Versus Dobutamine for Renal Function in Heart Failure (ELDOR)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02133105 |
Recruitment Status :
Completed
First Posted : May 7, 2014
Last Update Posted : February 25, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Cardiorenal Syndrome | Drug: Levosimendan Drug: Dobutamine | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 33 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | Efficacy of Intravenous Levosimendan Compared With Dobutamine on Renal Hemodynamics and Function in Chronic Heart Failure |
Actual Study Start Date : | April 2014 |
Actual Primary Completion Date : | May 2017 |
Actual Study Completion Date : | May 2017 |

Arm | Intervention/treatment |
---|---|
Active Comparator: Levosimendan
Levosimendan administration is initiated with a loading dose of 12μg/kg given over 10 min followed by a continuous infusion of 0.1 μg/kg/min for 65 min.
|
Drug: Levosimendan
Other Name: Simdax |
Active Comparator: Dobutamine
Dobutamine is given as a continuous infusion without a bolus dose. The infusion rate is started at 5.0 μg/kg/min for 10 minutes, and thereafter increased to 7,5 μg/kg/min for 65 min.
|
Drug: Dobutamine
Other Name: Dobutrex |
- Change in renal blood flow [ Time Frame: 75 min minus baseline ]Para-aminohippuric acid (PAH) infusion clearance
- Change in glomerular filtration rate [ Time Frame: 75 min minus baseline ]Chrome-ethylenediaminetetraacetic acid (EDTA) infusion clearance
- Change in renal vascular resistance [ Time Frame: 75 min minus baseline ]Renal blood flow divided by the difference between renal arterial pressure and renal venous pressure
- Change in central hemodynamics [ Time Frame: 75 min minus baseline ]Right atrial pressure, mean pulmonary arterial pressure, pulmonary capillary wedge pressure, mean arterial pressure, cardiac output, pulmonary vascular resistance and systemic vascular resistance measured with a pulmonary artery thermodilution catheter.
- Change in renal oxygen consumption and oxygen extraction [ Time Frame: 75 min minus baseline ]
Oxygen consumption: Renal blood flow multiplied by arterial-renal venous oxygen difference.
Oxygen extraction: Ratio of renal oxygen consumption to renal oxygen delivery
- Change in filtration fraction [ Time Frame: 75 min minus baseline ]Ratio of glomerular filtration rate to renal plasma flow

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Written, signed and dated informed consent
- Male and Female subjects ≥18 years of age
- Chronic congestive heart failure scheduled for right sided cardiac catheterization
- Left ventricular ejection fraction ≤ 40% determined by echocardiography
- Elevation of N Terminal-proBNP ≥ 500 ng/L
- Cardiorenal syndrome (30ml/min ≤ estimated GFR ≤ 80 ml/min (MDRD)
Exclusion Criteria:
- Acute heart failure, untreated
- Systolic blood pressure < 80 mmHg
- Tachycardia above 100 bpm
- Angina Canadian Cardiovascular Society (CCS) class III or higher
- Aortic stenosis
- Hypertrophic cardiomyopathy
- Restrictive cardiomyopathy
- The presence of kidney disease diagnosed before heart failure
- Administration of radiographic contrast < 1 week
- Radiographic contrast allergy
- In the Investigator's opinion, the patient has a clinically significant disease that could be adversely affected by study participation

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02133105
Sweden | |
Sahlgrenska University Hospital | |
Gothenburg, Sweden, 41345 |
Principal Investigator: | Kristjan Karason, MD, PhD | Sahlgrenska University Hospital, Department of Cardiology |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Göteborg University |
ClinicalTrials.gov Identifier: | NCT02133105 |
Other Study ID Numbers: |
2013-000986-36 2013-000986-36 ( EudraCT Number ) |
First Posted: | May 7, 2014 Key Record Dates |
Last Update Posted: | February 25, 2020 |
Last Verified: | February 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Supporting Materials: |
Study Protocol Statistical Analysis Plan (SAP) Informed Consent Form (ICF) Clinical Study Report (CSR) Analytic Code |
Heart failure Renal failure Inotropic drugs Levosimendan Dobutamine |
Cardio-Renal Syndrome Heart Failure Heart Diseases Cardiovascular Diseases Renal Insufficiency Kidney Diseases Urologic Diseases Simendan Dobutamine Cardiotonic Agents Vasodilator Agents Phosphodiesterase 3 Inhibitors Phosphodiesterase Inhibitors |
Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Protective Agents Physiological Effects of Drugs Sympathomimetics Autonomic Agents Peripheral Nervous System Agents Adrenergic beta-1 Receptor Agonists Adrenergic beta-Agonists Adrenergic Agonists Adrenergic Agents Neurotransmitter Agents |